AptaBio Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
AptaBio Therapeutics has a total shareholder equity of ₩61.4B and total debt of ₩13.6B, which brings its debt-to-equity ratio to 22.1%. Its total assets and total liabilities are ₩92.5B and ₩31.2B respectively.
Key information
22.1%
Debt to equity ratio
₩13.57b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩52.89b |
| Equity | ₩61.36b |
| Total liabilities | ₩31.16b |
| Total assets | ₩92.52b |
Financial Position Analysis
Short Term Liabilities: A293780's short term assets (₩57.5B) exceed its short term liabilities (₩818.0M).
Long Term Liabilities: A293780's short term assets (₩57.5B) exceed its long term liabilities (₩30.3B).
Debt to Equity History and Analysis
Debt Level: A293780 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A293780's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A293780 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A293780 has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 57.3% each year.